934 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Here's Why Loxo Oncology Soared as Much as 58.5% Today https://www.fool.com/investing/2017/06/05/heres-why-loxo-oncology-soared-as-much-as-585-toda.aspx?source=iedfolrf0000001 Jun 05, 2017 - The company announced interim data for three ongoing cancer trials.
Why Dynavax Technologies Corporation Stock Soared Today https://www.fool.com/investing/2017/06/05/why-dynavax-technologies-corporation-stock-soared.aspx?source=iedfolrf0000001 Jun 05, 2017 - A positive ASCO presentation for the experimental T-cell booster SD-101 is pushing Dynavax's shares higher today.
Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick https://www.fool.com/investing/general/2017/06/05/why-regeneron-is-quickly-becoming-my-top-biotech-s.aspx?source=iedfolrf0000001 Jun 05, 2017 - Approvals of new drugs with nine-figure sales potential and a full pipeline that can fuel future growth make this stock increasingly appealing at these prices.
Zoetis Just Hit an All-Time High: Here's Why the Stock Should Go Higher https://www.fool.com/investing/2017/06/03/zoetis-just-hit-an-all-time-high-heres-why-the-sto.aspx?source=iedfolrf0000001 Jun 03, 2017 - Can animal-health stock Zoetis keep its red-hot momentum going?
3 Top Dividend Stocks in Diabetes Treatment https://www.fool.com/investing/2017/05/31/3-top-dividend-stocks-in-diabetes-treatment.aspx?source=iedfolrf0000001 May 31, 2017 - Looking for great dividend stocks of drugmakers with diabetes treatments? Check out AstraZeneca, Pfizer, and Sanofi.
Gilead Single Tablet Regiment for HIV Good in Phase III http://www.zacks.com/stock/news/262556/gilead-single-tablet-regiment-for-hiv-good-in-phase-iii?cid=CS-ZC-FT-262556 May 31, 2017 - Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.
Big Pharma Diabetes Drugs Not So Sweet. What's in Store? http://www.zacks.com/stock/news/262544/big-pharma-diabetes-drugs-not-so-sweet-whats-in-store?cid=CS-ZC-FT-262544 May 31, 2017 - Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose http://www.zacks.com/stock/news/262529/mercks-hiv-drug-isentress-gets-fda-approval-for-higher-dose?cid=CS-ZC-FT-262529 May 31, 2017 - Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others http://www.zacks.com/research-daily/115367/top-analyst-reports-for-visa-ge-glaxosmithkline-others?cid=CS-ZC-FT-115367 May 26, 2017 - Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others
GlaxoSmithKline's New CEO Is Off to a Good Start https://www.fool.com/investing/2017/05/26/glaxosmithklines-new-ceo-is-off-to-a-good-start.aspx?source=iedfolrf0000001 May 26, 2017 - The latest quarter gave investors in this dividend stock an encouraging glimpse into the future.

Pages: 1...7677787980818283848586...94

<<<Page 81>